Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure

被引:21
|
作者
Huang, Dong-Hui [1 ]
Sun, Hao [1 ]
Shi, Jing-Pu [1 ]
机构
[1] China Med Univ, Dept Clin Epidemiol & Evidence Based Med, Inst Cardiovasc Dis, Hosp 1, Shenyang 110001, Liaoning, Peoples R China
关键词
Biomarker; Diagnosis; Heart Failure; Meta-analysis; Soluble Suppression of Tumorigenicity-2; RECEPTOR FAMILY-MEMBER; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; EJECTION FRACTION; PROGNOSTIC UTILITY; ACUTE DYSPNEA; ST2; BIOMARKERS; ASSOCIATION; GALECTIN-3;
D O I
10.4103/0366-6999.177000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent. Here, we performed a meta-analysis to assess the role of sST2 in the diagnosis of HF. Methods: We searched PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database from inception to April 2015. Studies that investigated the diagnostic role of sST2 for HF were reviewed. The numbers of true-positive, false-positive, false-negative, and true-negative results were extracted to calculate pooled diagnostic odds ratio (DOR) with 95% confidence interval (CI) and the summary receiver operating characteristic curve and area under the curve (AUC). The Spearman correlation coefficient was used to check the threshold effect. The Cochran Q statistic (P < 0.05) and the inconsistency index (I-2 > 50%) were used to assess the nonthreshold effect. Meta-regression was conducted to explore the source of heterogeneity; subgroup analysis showed the results in different subgroups. Finally, the Deeks' test was performed to assess the publication bias. Results: Nine articles including 10 studies were included in the meta-analysis. The pooled sensitivity was 0.84 (95% CI: 0.81-0.86), and pooled specificity was 0.74 (95% CI: 0.72-0.76). The summary DOR was 8.49 (95% CI: 4.54-15.86), and AUC was 0.81 (standard error: 0.03). The Spearman correlation coefficient identified the nonsignificant threshold effect (coefficient = 0.49, P = 0.148), but the nonthreshold effect heterogeneity was significant (Cochran Q = 58.52, P < 0.0001; I-2 = 84.6%). Meta-regression found that characteristics of controls might be the suggestive source of nonthreshold effect heterogeneity (P = 0.095). Subgroup analysis found that DOR was 5.65 and 7.86, respectively for the controls of hospital patients and healthy populations. Deeks' test demonstrated that there was no publication bias (P = 0.616). Conclusion: The meta-analysis illustrated that sST2 might play a role in diagnosing HF.
引用
收藏
页码:570 / 577
页数:8
相关论文
共 50 条
  • [1] Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
    Huang Dong-Hui
    Sun Hao
    Shi Jing-Pu
    中华医学杂志英文版, 2016, 129 (05) : 570 - 577
  • [2] Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
    Oncel, Can Ramazan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2018, 19 (03): : 228 - 228
  • [3] Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure A Meta-Analysis
    Aimo, Alberto
    Vergaro, Giuseppe
    Passino, Claudio
    Ripoli, Andrea
    Ky, Bonnie
    Miller, Wayne L.
    Bayes-Genis, Antoni
    Anand, Inder
    Januzzi, James L.
    Emdin, Michele
    JACC-HEART FAILURE, 2017, 5 (04) : 280 - 286
  • [4] Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
    Gul, Ibrahim
    Yucel, Oguzhan
    Zararsiz, Abdullah
    Demirpence, Ozlem
    Yucel, Hasan
    Zorlu, Ali
    Yilmaz, Mehmet Birhan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 18 (03): : 200 - 205
  • [5] Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure
    Aimo, Alberto
    Vergaro, Giuseppe
    Ripoli, Andrea
    Bayes-Genis, Antoni
    Figal, Domingo A. Pascual
    de Boer, Rudolf A.
    Lassus, Johan
    Mebazaa, Alexandre
    Gayat, Etienne
    Breidthardt, Tobias
    Sabti, Zaid
    Mueller, Christian
    Brunner-La Rocca, Hans-Peter
    Tang, W. H. Wilson
    Grodin, Justin L.
    Zhang, Yuhui
    Bettencourt, Paulo
    Maisel, Alan S.
    Passino, Claudio
    Januzzi, James L.
    Emdin, Michele
    JACC-HEART FAILURE, 2017, 5 (04) : 287 - 296
  • [6] Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure
    Sun, Yanxiang
    Feng, Li
    Hu, Bing
    Dong, Jianting
    Zhang, Liting
    Huang, Xuansheng
    Yuan, Yong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [7] Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis
    Shi, Yujiao
    Liu, Jiangang
    Liu, Chunqiu
    Shuang, Xiong
    Yang, Chenguang
    Qiao, Wenbo
    Dong, Guoju
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [8] Prognostic and Diagnostic Value of Plasma Soluble Suppression of Tumorigenicity-2 Concentrations in Acute Respiratory Distress Syndrome
    Bajwa, Ednan K.
    Volk, Jessica A.
    Christiani, David C.
    Harris, R. Scott
    Matthay, Michael A.
    Thompson, B. Taylor
    Januzzi, James L.
    CRITICAL CARE MEDICINE, 2013, 41 (11) : 2521 - 2531
  • [9] Soluble Suppression of Tumorigenicity-2 (sst2) Predicts Mortality and Right Heart Failure in Lvad Patients
    Numan, L.
    Aarts, E.
    Ramjankhan, F.
    Van der Meer, M. G.
    Oerlemans, M.
    De Jonge, N.
    Oppelaar, A.
    Kemperman, H.
    Asselbergs, F.
    Van Laake, L. W.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S364 - S365
  • [10] Diagnostic and Prognostic Values of Soluble Suppression of Tumorigenicity-2 Measurements in the Treatment Assessment of Adult Patients with Congenital Heart Disease and Cardiac Failure
    Khajali, Zahra
    Firouzi, Ata
    Arabian, Maedeh
    Naderi, Nasim
    Maleki, Majid
    Saedi, Sedigheh
    Aliramezany, Maryam
    INTERNATIONAL CARDIOVASCULAR RESEARCH JOURNAL, 2020, 14 (04) : 127 - 131